Eczema Clinical Trial
Enrolling Now

Clinics: Greater Manchester, Lancashire, Merseyside, South Staffordshire, South Yorkshire and Teesside

Therapy Area: Atopic Dermatitis

Gender and Age: Males & Females aged 12 +

Reimbursement: Eligible participants will be reimbursed for travel to all visits (up to a max. of £50 per visit) and will receive refreshments for visits lasting more than 3 hours.

About The Research...

Eczema also known as atopic dermatitis is one of the most common types of skin condition and affects about 10% to 20% of the population, and up to 25% of children. Common features of this inflammatory skin condition include itching and dryness. Eczema often relapses, meaning symptoms will improve for a while but then return.

Many people with eczema may manage their condition and relieve their symptoms using moisturising treatments and drugs such as corticosteroid creams or tablets and phototherapy (treatment with light). However, for about one-fifth of people with moderate to severe forms of eczema these treatments are not as effective especially in the long term, and currently there is no cure for the condition.

At MAC Clinical Research we understand there is a need for new and improved treatments, and we are conducting a clinical trial to test a new treatment.

750 eligible participants worldwide will receive the study drug or matching placebo (a ‘dummy medication’ containing no active ingredient or drug) by subcutaneous injection (an injection under the skin). Participants will initially have a 66% (2 in 3) chance of receiving nemolizumab and a 33% (1 in 3) chance of receiving placebo. There will be up to 17 visits to clinic and the trial will last up to a max. 60 weeks.

Previous clinical studies of Nemolizumab on adults with eczema have shown some statistically significant improvements in scores that rate eczema severity and itch when compared to placebo. A full description of the study will be given before you decide to take part, both over the phone and during an appointment at a MAC clinic. This will include you receiving the full patient information sheet (PIS).

Reimbursement: 

Eligible participants will be reimbursed for travel to all visits (up to a max. of £50 per visit) and will receive refreshments for visits lasting more than 3 hours.

Criteria

Key Inclusion Criteria:

  • Male or female aged 12+
  • Diagnosis of eczema for at least the 2 years
  • Minimum weight 30kg

 

Key Exclusion Criteria:

  • Intolerance or allergies to topical corticosteroids
  • COPD or any uncontrolled respiratory conditions

 

Other eligibility criteria will apply. Please contact MAC for more information.

Please click the button below at the bottom of the screen to refer yourself, or a friend, for this study.

If you are under the age of 13 years, your form must be completed by an adult.  We are not allowed to take data from children under the age of 13 years. Thank you.

Any other information

If you are eligible you will receive a comprehensive health screen. Your GP will be fully informed of your participation and provided with any information relevant to your healthcare.

MAC Clinical Research is conducting a trial to evaluate a potential new treatment for eczema.

If you would like more information, please fill in the form below and we will be in touch…

Alternatively, please call our recruitment team on freephone 0800 633 5507.

  • (You can enter any supporting information here)
Data Privacy Statement

Know someone who may be interested in taking part? Share this page here:

Share on facebook
Facebook
Share on twitter
Twitter
Share on whatsapp
WhatsApp
Share on email
Email